July 4, 2022



Neurocrine Biosciences Earns RS Rating Upgrade

2 min read

In a welcome move, Neurocrine Biosciences (NBIX) saw its Relative Strength Rating improve from 69 to 74 on Friday.


When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.

This exclusive rating from Investor’s Business Daily identifies market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock’s price performance over the last 52 weeks holds up against all the other stocks in our database.

Over 100 years of market history shows that the stocks that go on to make the biggest gains tend to have an 80 or better RS Rating in the early stages of their moves. See if Neurocrine Biosciences can continue to rebound and clear that threshold.

See How IBD Helps You Make More Money In Stocks

Neurocrine Biosciences is trying to complete a cup without handle with a 108.11 entry. See if it can break out in heavy volume.

Earnings growth declined in the company’s latest report from 0% to -96%, but sales rose from 15% to 26%.

Neurocrine Biosciences earns the No. 13 rank among its peers in the Medical-Biomed/Biotech industry group. Vertex Pharmaceuticals (VRTX) and Amphastar Pharmaceutcls (AMPH) are also among the group’s highest-rated stocks.


Biotech And Pharmaceutical Industry And Stock News

Stocks With Rising Relative Strength Ratings

Why Should You Use IBD’s Relative Strength Rating?

How Relative Strength Line Can Help You Judge A Stock

See How To Reduce Risk, Increase Profits With Swing Trading

Copyright © All rights reserved. | Newsphere by AF themes.